MX2010001446A - Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple. - Google Patents
Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple.Info
- Publication number
- MX2010001446A MX2010001446A MX2010001446A MX2010001446A MX2010001446A MX 2010001446 A MX2010001446 A MX 2010001446A MX 2010001446 A MX2010001446 A MX 2010001446A MX 2010001446 A MX2010001446 A MX 2010001446A MX 2010001446 A MX2010001446 A MX 2010001446A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- multiple sclerosis
- sphingosine
- pyrimidine
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La invención se refiere a compuestos de Fórmula (I): (ver fórmula I) en donde X, W, Q, R, R1 y R2 tienen los significados indicados en la reivindicación 1. Los compuestos son útiles, por ejemplo, en el tratamiento de trastornos autoinmunes, como, por ejemplo, la esclerosis múltiple.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07113992 | 2007-08-08 | ||
US96486407P | 2007-08-15 | 2007-08-15 | |
PCT/EP2008/059933 WO2009019167A1 (en) | 2007-08-08 | 2008-07-29 | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010001446A true MX2010001446A (es) | 2010-03-01 |
Family
ID=38985492
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010001446A MX2010001446A (es) | 2007-08-08 | 2008-07-29 | Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple. |
Country Status (15)
Country | Link |
---|---|
US (2) | US8399448B2 (es) |
EP (1) | EP2183224B1 (es) |
JP (1) | JP5508265B2 (es) |
KR (1) | KR20100051849A (es) |
CN (1) | CN101790519B (es) |
AR (1) | AR067877A1 (es) |
AU (1) | AU2008285722B2 (es) |
BR (1) | BRPI0814975A2 (es) |
CA (1) | CA2696565C (es) |
EA (1) | EA201070238A1 (es) |
ES (1) | ES2445405T3 (es) |
IL (1) | IL203578A (es) |
MX (1) | MX2010001446A (es) |
WO (1) | WO2009019167A1 (es) |
ZA (1) | ZA201000585B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008302746B2 (en) * | 2007-09-20 | 2014-07-03 | Amgen Inc. | 1-(4-(benzylbenzamid0) -benzyl) azetidine-3-carboxylic acid derivatives and related compounds as SlP receptor modulators for the treatment of immune disorders |
BRPI0916812B8 (pt) | 2008-07-23 | 2022-10-18 | Arena Pharm Inc | Derivados do ácido 1,2,3,4-tetra-hidrociclopenta[b]indol-3-il)acético substituído úteis no tratamento de distúrbios autoimunes e inflamatórios, seu uso, composição farmacêutica que os compreende e processo de preparação |
CN105816453B (zh) | 2008-08-27 | 2021-03-05 | 艾尼纳制药公司 | 用于治疗自身免疫性病症和炎性病症的作为s1p1受体激动剂的经取代的三环酸衍生物 |
BR112012009670A2 (pt) | 2009-10-23 | 2016-05-17 | Allergan Inc | compostos de cumarina como moduladores de receptor com utilidade terapêutica |
EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
US9085581B2 (en) | 2010-03-03 | 2015-07-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof |
JP2013522240A (ja) * | 2010-03-17 | 2013-06-13 | グラクソ グループ リミテッド | スフィンゴシン1−リン酸1(s1p1)受容体作用薬として用いるためのピリミジン誘導体 |
MX2013011979A (es) * | 2011-04-14 | 2014-02-06 | Allergan Inc | Derivados de metilamina biciclica de fenilo como moduladores de los receptores de la esfingosina-1 fosfato. |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2014130572A1 (en) * | 2013-02-21 | 2014-08-28 | Allergan, Inc. | Substituted 6-methoxy-4-amino-n-phenyl-2-naphtamides as sphingosine receptor modulators |
CN103408501B (zh) * | 2013-08-14 | 2016-03-09 | 合肥医工医药有限公司 | 苄基嘧啶衍生物、其制备方法及其医药用途 |
TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺,其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
EA201691401A1 (ru) * | 2014-01-10 | 2016-11-30 | Ориджин Дискавери Текнолоджиз Лимитед | Индазольные соединения в качестве ингибиторов irak4 |
JP6479850B2 (ja) | 2014-01-13 | 2019-03-06 | アウリジーン ディスカバリー テクノロジーズ リミテッド | Irak4阻害剤としての二環式ヘテロシクリル誘導体 |
KR101499007B1 (ko) * | 2014-04-24 | 2015-03-05 | 고려대학교 산학협력단 | 염증성 질환의 예방 또는 치료용 약학 조성물 |
NZ734220A (en) | 2015-01-06 | 2022-01-28 | Arena Pharm Inc | Methods of treating conditions related to the s1p1 receptor |
CN108349891B (zh) | 2015-06-22 | 2022-04-05 | 艾尼纳制药公司 | 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐 |
AU2017322427B2 (en) | 2016-09-09 | 2021-12-23 | Incyte Corporation | Pyrazolopyridine derivatives as HPK1 modulators and uses thereof for the treatment of cancer |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
WO2018151873A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of primary biliary cholangitis |
RS64411B1 (sr) | 2017-03-31 | 2023-09-29 | Aurigene Oncology Ltd | Jedinjenja i kompozicije za lečenje hematoloških poremećaja |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
MX2020003666A (es) | 2017-10-31 | 2020-08-03 | Curis Inc | Compuestos y composiciones para el tratamiento de trastornos hematologicos. |
PL3755703T3 (pl) | 2018-02-20 | 2022-11-07 | Incyte Corporation | Pochodne n-(fenylo)-2-(fenylo)pirymidyno-4-karboksyamidu i związki pokrewne jako inhibitory hpk1 do leczenia nowotworu |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
CA3147918A1 (en) | 2019-08-06 | 2021-02-11 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
GB202213310D0 (en) * | 2022-09-12 | 2022-10-26 | Benevolentai Cambridge Ltd | New compounds and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69912823T2 (de) * | 1998-09-25 | 2004-09-23 | Astrazeneca Ab | Benzamid-derivate und ihre verwendung als cytokine inhibitoren |
JP2004534046A (ja) * | 2001-05-28 | 2004-11-11 | アベンティス・ファーマ・ソシエテ・アノニム | 化学誘導体および抗テロメラーゼ剤としてのその使用 |
US7220764B2 (en) | 2002-06-17 | 2007-05-22 | The Pennsylvania State University Research Foundation | Sphingosine kinase inhibitors |
TW200524880A (en) | 2003-10-21 | 2005-08-01 | Sankyo Co | Pyrimidine compounds |
MXPA06007076A (es) | 2003-12-19 | 2006-08-31 | Pharmacopeia Drug Discovery | Tiadiazoles como ligandos del receptor cxc y cc-quimiocina. |
US7919487B2 (en) | 2004-11-10 | 2011-04-05 | Synta Pharmaceuticals Corporation | Heteroaryl compounds |
TWI444379B (zh) * | 2007-06-29 | 2014-07-11 | Sunesis Pharmaceuticals Inc | 有用於作為Raf激酶抑制劑之化合物 |
-
2008
- 2008-07-29 CN CN2008801020927A patent/CN101790519B/zh not_active Expired - Fee Related
- 2008-07-29 AU AU2008285722A patent/AU2008285722B2/en not_active Ceased
- 2008-07-29 MX MX2010001446A patent/MX2010001446A/es not_active Application Discontinuation
- 2008-07-29 CA CA2696565A patent/CA2696565C/en not_active Expired - Fee Related
- 2008-07-29 EA EA201070238A patent/EA201070238A1/ru unknown
- 2008-07-29 ES ES08775369.5T patent/ES2445405T3/es active Active
- 2008-07-29 EP EP08775369.5A patent/EP2183224B1/en active Active
- 2008-07-29 US US12/671,996 patent/US8399448B2/en active Active
- 2008-07-29 WO PCT/EP2008/059933 patent/WO2009019167A1/en active Application Filing
- 2008-07-29 JP JP2010519431A patent/JP5508265B2/ja not_active Expired - Fee Related
- 2008-07-29 BR BRPI0814975-5A2A patent/BRPI0814975A2/pt not_active IP Right Cessation
- 2008-07-29 KR KR1020107005173A patent/KR20100051849A/ko not_active Application Discontinuation
- 2008-08-07 AR ARP080103456A patent/AR067877A1/es not_active Application Discontinuation
-
2010
- 2010-01-26 ZA ZA2010/00585A patent/ZA201000585B/en unknown
- 2010-01-28 IL IL203578A patent/IL203578A/en active IP Right Grant
-
2012
- 2012-12-12 US US13/711,893 patent/US9150519B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101790519B (zh) | 2013-10-16 |
IL203578A (en) | 2014-02-27 |
CA2696565C (en) | 2017-02-14 |
EP2183224B1 (en) | 2013-11-06 |
CN101790519A (zh) | 2010-07-28 |
US9150519B2 (en) | 2015-10-06 |
ES2445405T3 (es) | 2014-03-03 |
JP5508265B2 (ja) | 2014-05-28 |
AU2008285722B2 (en) | 2013-06-20 |
EP2183224A1 (en) | 2010-05-12 |
BRPI0814975A2 (pt) | 2015-02-03 |
KR20100051849A (ko) | 2010-05-18 |
EA201070238A1 (ru) | 2010-08-30 |
AU2008285722A1 (en) | 2009-02-12 |
US20100210619A1 (en) | 2010-08-19 |
AR067877A1 (es) | 2009-10-28 |
ZA201000585B (en) | 2011-04-28 |
US8399448B2 (en) | 2013-03-19 |
WO2009019167A1 (en) | 2009-02-12 |
CA2696565A1 (en) | 2009-02-12 |
JP2010535734A (ja) | 2010-11-25 |
US20130109669A1 (en) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010001446A (es) | Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple. | |
MX2010003612A (es) | Derivados de oxadiazol. | |
MX2010003614A (es) | Compuestos de diarilo oxadiazol. | |
MY148253A (en) | Azaadamantane derivatives and methods of use | |
TN2010000140A1 (en) | Compositions and methods for use antibodies against sclerostin | |
MX2011010451A (es) | Derivados de oxadiazol. | |
WO2010033701A3 (en) | Inhibitors of sphingosine kinase 1 | |
MX2011011661A (es) | Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750. | |
MY159575A (en) | Dihydroorotate dehydrogenase inhibitors | |
PT1984357E (pt) | Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes | |
TW200726753A (en) | 2,4-diamino-pyrimidines as aurora inhibitors | |
PT2150530E (pt) | Derivados de sulfonamida substituídos | |
TW200744586A (en) | Therapeutic compounds | |
UA99936C2 (en) | Biaryl substituted azabicyclic alkane derivatives | |
MX2010007026A (es) | Derivados de triazoloxadiazoles. | |
MX2010007392A (es) | Antagonistas de trpa1. | |
UA92670C2 (ru) | Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе | |
MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
MX2010007391A (es) | Antagonistas de trpa1. | |
TW200714587A (en) | Biphenyl compounds useful as muscarinic receptor antagonists | |
GEP20125547B (en) | (aza) indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor | |
MX2009011059A (es) | Aminopirimidinas utiles como inhibidores de cinasas. | |
MX2012004548A (es) | Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central. | |
TW200734324A (en) | Therapeutic agents | |
TW200613317A (en) | Steroid prodrugs with androgenic action |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |